SHBG SHBG intronic regulatory variant

SHBG rs858518 — The SHBG-Lowering Haplotype Variant

[Sex hormone-binding globulin (SHBG) | A liver-produced transport protein that binds
testosterone and estradiol in circulation, controlling how much hormone is biologically
active] is a critical gatekeeper for sex hormone action throughout the body. Only 1–2%
of testosterone and estradiol circulate as free, bioactive hormones — the rest is bound
to SHBG (about 44%) or albumin. The SHBG gene on chromosome 17 encodes this protein, and
variants within it directly influence circulating SHBG protein levels. rs858518 is an
intronic variant that sits within the SHBG gene and participates in a co-inherited
haplotype — together with the nearby intronic variant rs727428 — that reduces SHBG
production in the liver.

The Mechanism

Rs858518 (chr17:7,629,707, GRCh38) is located in an intron of the SHBG gene and does
not directly alter the SHBG protein sequence. Instead, it likely tags a regulatory
element or is in strong linkage disequilibrium with a causal variant that affects SHBG
gene expression. Haplotype analysis of 11 tagging SNPs across the SHBG locus showed
that rs858518 and the nearby rs727428 act in concert to lower SHBG levels, while this
lowering effect is counteracted when rs6259 (Asp356Asn), a coding variant in exon 8,
is also present on the same haplotype background | Thompson et al. Cancer Epidemiology
Biomarkers & Prevention 2008. This
three-way interaction illustrates how the SHBG locus functions as a network of
co-acting variants rather than a single deterministic SNP.

The practical consequence is straightforward: the A allele at rs858518 participates in
a haplotype that reduces the amount of SHBG the liver makes. Lower SHBG means more
testosterone and estradiol remain unbound — biologically active — even when total hormone
levels appear normal on standard bloodwork. Because SHBG binds testosterone with
approximately five times higher affinity than estradiol, the impact is felt most strongly
through testosterone bioavailability.

The Evidence

The foundational evidence for rs858518 comes from a 2008 study by Thompson et al. of
up to 6,622 breast cancer cases and 6,784 controls, with SHBG level analysis in 1,134
healthy postmenopausal women | Thompson DJ et al. Identification of common variants in
the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in
postmenopausal women. Cancer Epidemiology Biomarkers & Prevention 2008.
That work identified a haplotype containing rs858518 and rs727428 as the primary SHBG-
lowering signal within the SHBG locus, accounting for a substantial fraction of
inter-individual variance in circulating SHBG.

For the fertility-relevant phenotype of SHBG levels in men with and without infertility,
rs727428 — the strong LD partner of rs858518 — provides the most precise effect estimate.
In a study of 1,505 men (540 young controls, 641 infertile patients, 324 pregnant women's
partners) | Grigorova et al. Genetics of Sex Hormone-Binding Globulin and Testosterone
Levels in Fertile and Infertile Men of Reproductive Age. J Endocrine Society 2017,
each copy of the rs727428 T allele (the SHBG-lowering allele) was associated with
−3.74 nmol/L lower SHBG (SE 0.57, P=7.3×10⁻¹¹). Notably, free testosterone did not
differ significantly across genotypes, suggesting compensatory total testosterone
adjustments maintain free hormone homeostasis in healthy men. No direct associations
with male infertility parameters were detected for this variant, consistent with the
view that rs858518/rs727428 acts on the SHBG set-point rather than spermatogenesis
directly.

For metabolic disease, a 2019 Uighur population case-control study comparing 114 men
with T2DM to 173 healthy controls | Quan et al. Association between sex hormone binding
globulin gene polymorphism and type 2 diabetes mellitus. Int J Clin Exp Pathol 2019
found that the four-SNP haplotype rs858518-rs3760213-rs1799941-rs6257 with sequence
TCGC was significantly more frequent in T2DM cases (P=0.033), placing rs858518 within
a broader SHBG haplotype block associated with diabetes risk in this population.

The most recent evidence implicates rs858518 specifically in female VTE risk. A 2024
two-sample Mendelian randomization using UK Biobank and FinnGen data | Tian et al.
The genetic effects of hormones modulated by the pituitary-thyroid/adrenal/gonadal axis
on the risk of developing VTE. BMC Cardiovascular Disorders 2024
identified rs858518 as the only SHBG SNP associated with increased female VTE risk,
operating through an estradiol-mediated pathway. The authors proposed rs858518 as a
"potential prevention and treatment target for female VTE."

Practical Implications

Lower SHBG from this haplotype means higher bioavailable testosterone and estradiol.
In women, elevated free androgen is the biochemical hallmark of PCOS — hyperinsulinemia
and this genetic tendency toward lower SHBG may act together to amplify the free androgen
excess that drives PCOS symptoms. In men, the effect size (-3.74 nmol/L per allele) is
moderate in absolute terms; free testosterone is largely maintained through compensatory
mechanisms in metabolically healthy individuals, but the SHBG-lowering allele shifts the
balance toward higher free-to-total hormone ratios that matter most in clinical edge cases
(borderline hypogonadism, anabolic sensitivity, metabolic disease).

For the diabetes-SHBG connection: low SHBG is itself a biomarker of insulin resistance —
insulin suppresses SHBG production via HNF4A downregulation. Carrying the rs858518 A
allele sets a genetically lower SHBG baseline, potentially compounding the SHBG suppression
that accompanies metabolic dysfunction. Monitoring fasting glucose, insulin sensitivity,
and SHBG levels together provides the clearest picture.

Interactions

rs727428 (SHBG intron 4, +1091 C>T): The primary LD partner of rs858518. These two
variants are co-inherited and likely represent the same haplotype signal — the SHBG-
lowering effect reported for rs858518 in haplotype analyses is quantitatively validated
through the rs727428 direct association (−3.74 nmol/L per T allele). A compound action
for the rs858518 AA + rs727428 TT double-homozygous state (lowest SHBG haplotype) could
capture the full extent of SHBG suppression from this intragenic haplotype block.

rs6259 (SHBG Asp356Asn, p.Asp356Asn): This coding variant in exon 8 neutralizes the
SHBG-lowering effect of the rs858518/rs727428 haplotype when present on the same
chromosomal background, based on Thompson 2008 haplotype analysis. Users who carry AA at
rs858518 and the D356N variant at rs6259 may not show the expected SHBG reduction.

rs1799941 (SHBG promoter): This promoter variant independently increases SHBG and is
already tracked in the platform's hormones-sleep category. The rs858518 and rs1799941
variants exert opposing effects on SHBG — carrying the rs858518 AA (lowering) and
rs1799941 AA (raising) genotypes simultaneously represents a tug-of-war at the SHBG set-
point, with net effect depending on additional haplotype context.

Compound action proposal for rs858518 AA + rs727428 TT: Both variants on the SHBG-
lowering haplotype, homozygous at both positions, represent the lowest-SHBG genotypic
state within this locus. The combined recommendation would be: monitor free testosterone
(not just total), monitor fasting insulin and HOMA-IR annually, and for women of
reproductive age, screen for PCOS-related free androgen excess if symptoms are present.
Evidence level: moderate (derivable from Grigorova 2017 and Thompson 2008 haplotype data).